According to preliminary results from a phase I/II trial, cord blood–derived natural killer cells complexed with AFM13, a bispecific antibody, showed efficacy in patients with relapsed/refractory CD30+ lymphomas. Complete responses were seen, and treatment was extremely well tolerated.

You do not currently have access to this content.